

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements best summarizes results from the Phase III ADAURA trial evaluating osimertinib versus placebo as adjuvant therapy after complete tumor resection for patients with early-stage non-small cell lung cancer (NSCLC) with EGFR mutations?**
  - a. A clinically meaningful benefit was observed with adjuvant osimertinib among patients with Stage II/IIIA disease**
  - b. No clinically meaningful benefit was observed with adjuvant osimertinib among patients with Stage II/IIIA disease
- 2. Which of the following statements is true regarding the use of durvalumab consolidation after chemoradiation therapy for patients with locally advanced NSCLC?**
  - a. A significant survival benefit is derived among patients with EGFR mutations
  - b. No survival benefit has been reported for patients with EGFR mutations**
- 3. Which of the following conditions has been reported as an immune-mediated adverse event experienced by patients receiving immune checkpoint inhibitor therapy?**
  - a. New secondary cancer, such as myelodysplastic syndromes
  - b. Ocular toxicity, such as central serous retinopathy
  - c. Endocrinopathy, such as hypothyroidism**
- 4. The Phase II DESTINY-Lung01 study evaluated the antibody-drug conjugate trastuzumab deruxtecan in patients with nonsquamous NSCLC and which targetable mutations?**
  - a. KRAS G12C mutations
  - b. EGFR mutations
  - c. HER2 mutations**
  - d. MET exon 14 skipping mutations